Skye Bioscience (SKYE) Q3 2024 earnings summary

Executive summary

• Transitioned to a metabolic health focus, launching the Phase 2 CBEYOND obesity trial for nimacimab, a peripherally restricted CB1 inhibitor, with strong clinical and preclinical progress and robust enrollment.

• Nimacimab demonstrated up to 16% dose-dependent weight loss in preclinical models, with significant fat loss and lean mass preservation.

• Team expansion included the appointment of Dr. Puneet Arora as Chief Medical Officer and Paul Grayson as Chairman, along with other experienced board members.

• Discontinued ocular program after negative Phase 2a results, reallocating resources to metabolic pipeline.

• Completed two PIPE financings in early 2024, raising $83.6M net, and uplisted to NASDAQ.

Financial highlights

• Research and development expenses rose to $4.9 million in Q3 2024 from $1.3 million in Q3 2023, mainly due to nimacimab clinical trial and manufacturing costs.

• General and administrative expenses increased to $4.6 million from $2.2 million year-over-year, driven by stock-based compensation and professional fees.

• Net loss for Q3 2024 was $3.9 million, a significant improvement from $24.9 million in Q3 2023, primarily due to the absence of a $21.2 million asset acquisition expense in the prior year.

• Cash and cash equivalents totaled $76.5 million as of September 30, 2024, including $9.1 million in restricted cash.

• Recognized $1 million in interest income and $4.6 million in income from derecognition of liabilities and legal recoveries.

Outlook and guidance

• Interim Phase 2 CBEYOND trial data expected in Q2 2025 at 50% enrollment, with topline data by end of 2025.

• Cash runway extended through Q3 2027, supporting ongoing clinical and operational milestones.

• Quarterly cash burn is $6 million, expected to rise to $9 million in 2025.

• No revenue expected until regulatory approval and commercialization of nimacimab or future candidates.